Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Wuhan University

Headquarters: Wuhan, Hubei, China
Year Founded: 1893
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Apr 1, 2025
Distillery Therapeutics

Inhibiting T cell PCIF1 for antitumor immunity

BioCentury | Jan 28, 2025
Distillery Therapeutics

Inhibiting ZDHHC3 for HCC antitumor immunity

BioCentury | Dec 20, 2024
Editor's Commentary

Don’t sleep on China’s academic innovation: a Perspective

Forget the ‘fast follower’ narrative: Plenty of new target biology is now coming from Chinese university labs
BioCentury | Sep 6, 2024
Distillery Therapeutics

Inhibition of DUSP18 for antitumor immunity in colorectal cancer

BioCentury | May 31, 2024
Distillery Therapeutics

NUDT1 PROTAC for MYC-driven cancers

BioCentury | Apr 30, 2024
Distillery Therapeutics

Overexpressing SIKE1 for MASH

BioCentury | Jun 2, 2023
Discovery & Translation

Single-cell T cell atlas identifies new subsets; plus CoRegen’s cell therapy and more

BioCentury’s roundup of translational news
BioCentury | Mar 8, 2023
Distillery Therapeutics

A universal vaccine antigen for SARS-CoV-2

BioCentury | Nov 8, 2022
Distillery Therapeutics

Inhibiting CDK14 for TNBC

Items per page:
1 - 10 of 46